- Home
- BCTXZ vs PX Comparison
BCTXZ vs PX Comparison
Compare BCTXZ & PX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTXZ
- PX
- Stock Information
- Founded
- BCTXZ N/A
- PX 1992
- Country
- BCTXZ Canada
- PX United States
- Employees
- BCTXZ 12
- PX N/A
- Industry
- BCTXZ
- PX Investment Managers
- Sector
- BCTXZ
- PX Finance
- Exchange
- BCTXZ Nasdaq
- PX Nasdaq
- Market Cap
- BCTXZ N/A
- PX N/A
- IPO Year
- BCTXZ N/A
- PX 2021
- Fundamental
- Price
- BCTXZ $0.94
- PX $11.66
- Analyst Decision
- BCTXZ
- PX Buy
- Analyst Count
- BCTXZ 0
- PX 8
- Target Price
- BCTXZ N/A
- PX $14.25
- AVG Volume (30 Days)
- BCTXZ N/A
- PX 491.4K
- Earning Date
- BCTXZ N/A
- PX 05-08-2025
- Dividend Yield
- BCTXZ N/A
- PX 1.19%
- EPS Growth
- BCTXZ N/A
- PX N/A
- EPS
- BCTXZ N/A
- PX 0.16
- Revenue
- BCTXZ N/A
- PX $298,000,000.00
- Revenue This Year
- BCTXZ N/A
- PX $1.68
- Revenue Next Year
- BCTXZ N/A
- PX $16.79
- P/E Ratio
- BCTXZ N/A
- PX $71.79
- Revenue Growth
- BCTXZ N/A
- PX 18.92
- 52 Week Low
- BCTXZ N/A
- PX $7.62
- 52 Week High
- BCTXZ N/A
- PX $14.28
- Technical
- Relative Strength Index (RSI)
- BCTXZ N/A
- PX 56.68
- Support Level
- BCTXZ N/A
- PX $10.84
- Resistance Level
- BCTXZ N/A
- PX $11.82
- Average True Range (ATR)
- BCTXZ 0.00
- PX 0.35
- MACD
- BCTXZ 0.00
- PX 0.10
- Stochastic Oscillator
- BCTXZ 0.00
- PX 88.41
About BCTXZ BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.